Prevalence, associated factors, and prognostic value of sarcopenia in patients with acute exacerbated chronic obstructive pulmonary disease: A cohort study

• Published in: Clinical nutrition ESPEN Vol. 42; pp. 188 - 194
• Main Authors: Espíndola de Araújo, Bruna, Teixeira, Paula Portal, Valduga, Kamila, da Silva Fink, Jaqueline, Silva, Flávia Moraes
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-04-2021
• Subjects: COPD; Hospitalization; Sarcopenia; Sarcopenia; Hospitalization; COPD
• ISSN: 2405-4577; 2405-4577
• DOI: 10.1016/j.clnesp.2021.01.042

Besides pulmonary dysfunctions, patients with chronic obstructive pulmonary disease (COPD) also frequently have systemic comorbidities. Among these, sarcopenia is associated with worse pulmonary function and clinical outcomes. Patients with acute exacerbated COPD (AECOPD) have increased systemic inflammation, which can intensify muscle dysfunction. Therefore, the present study aimed to evaluate the prevalence of sarcopenia in AECOPD patients and assess the associated factors and their prognostic value. As a secondary aim, we also assessed the performance of calf circumference (CC) to diagnose this condition.
Prospective cohort study in a Brazilian public hospital with AECOPD patients. Sarcopenia was assessed according to the recommendations from the European Working Group of Sarcopenia in Older People Consensus 2 (EWGSOP2); namely, reduced handgrip strength (HGS) combined with low fat-free mass index (FFMI) or CC. Data on clinical, nutritional, and sociodemographic features were collected. The evaluated clinical outcomes were the length of hospital stay (LOS), admission in intensive care units (ICUs), and in-hospital death.
Among 208 patients (54.8% females, 67.6 ± 10.1 years) evaluated, 16.3% presented sarcopenia. Malnutrition (odds ratio [OR] = 16.50, 95% confidence interval [CI] 3.58–76.08), and disease stages III-IV (OR = 4.05 95%CI 1.20–13.76) were associated with the presence of sarcopenia. The CC showed satisfactory performance in diagnosing sarcopenia as compared to FFMI as a marker of reduced muscle mass (kappa = 0.703; area under the receiver operating characteristic [AUC ROC] curve = 0.886; 95%CI 0.811–0.961). Sarcopenia was not associated with clinical outcomes.
Almost 20% of patients in this study presented sarcopenia. Malnutrition and advanced Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage were associated with increased chances of this condition in AECOPD patients. Reduced HSG combined with low CC may be an alternative when FFMI not be obtained for sarcopenia diagnosis.
•Sarcopenia affects 15% of patients with exacerbation of chronic obstructive pulmonary disease.•Malnutrition and severe disease stages are factors associated with sarcopenia.•The calf circumference can be applied as muscle mass marker in sarcopenia diagnosis.